Sarasin & Partners LLP Acquires 11,818 Shares of Thermo Fisher Scientific Inc. $TMO

Sarasin & Partners LLP raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 268,407 shares of the medical research company’s stock after acquiring an additional 11,818 shares during the period. Thermo Fisher Scientific comprises 1.2% of Sarasin & Partners LLP’s holdings, making the stock its 28th biggest holding. Sarasin & Partners LLP owned approximately 0.07% of Thermo Fisher Scientific worth $124,015,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TMO. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth $2,264,615,000. Soundwatch Capital LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth $807,713,000. Flossbach Von Storch SE increased its holdings in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after purchasing an additional 1,314,182 shares in the last quarter. EdgePoint Investment Group Inc. raised its position in Thermo Fisher Scientific by 282.5% in the second quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after purchasing an additional 977,127 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Thermo Fisher Scientific by 58.2% during the second quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock worth $929,828,000 after purchasing an additional 843,267 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.8%

Shares of Thermo Fisher Scientific stock opened at $567.01 on Friday. The firm has a market cap of $213.03 billion, a price-to-earnings ratio of 32.76, a PEG ratio of 4.21 and a beta of 0.90. The stock’s 50-day moving average is $569.01 and its 200 day moving average is $497.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase plan on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $597.68, for a total value of $4,131,761.84. Following the transaction, the executive vice president directly owned 14,367 shares in the company, valued at $8,586,868.56. The trade was a 32.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on TMO shares. Argus lifted their target price on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective for the company in a report on Sunday, December 7th. Hsbc Global Res raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. Finally, The Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $616.60.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.